Back to results
US 12,653,863 B2Granted
FGF21 compositions for treatment or prevention of neovascularization of the eye and methods therefor
AssigneeChildren's Medical Center Corporation
InventorsLois Smith, Zhongjie Fu
Life of this patent
Estimating the term…
Abstract
The instant disclosure provides methods and compositions related to discovery of a long-acting FGF21 as a therapeutic target for treatment or prevention of neovascular eye diseases or disorders that are characterized by angiogenesis, or of vascular diseases of the eye. Therapeutic and/or prophylactic uses and compositions of long-acting FGF21 are described.
Claims12
A method for decreasing neovascularization or angiogenesis in the eye of a subject, the method comprising:
- (a) identifying a subject having neovascularization or angiogenesis in the eye;
- and
- (b) administering a pharmaceutical composition comprising a stabilized fibroblast growth factor 21 (FGF21) agent to the subject, and
- thereby treating neovascularization or angiogenesis in the eye of the subject, wherein the stabilized FGF21 agent comprises an FGF21 polypeptide conjugated to an antibody scaffold.
1 more element
Dependencies are inferred from the claim text.